These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35437232)
21. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
22. [FUTURE THERAPIES FOR CYSTIC FIBROSIS]. Fajac I Rev Prat; 2015 Oct; 65(8):1106-8. PubMed ID: 26749719 [TBL] [Abstract][Full Text] [Related]
23. [Cystic fibrosis prognosis in Europa : chronicle of an announced dilemma]. Lebecque P; Thimmesch M Rev Med Liege; 2021 Mar; 76(3):202-207. PubMed ID: 33682390 [TBL] [Abstract][Full Text] [Related]
25. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
26. Ivacaftor for the treatment of cystic fibrosis in children under six years of age. Aoyama BC; Mogayzel PJ Expert Rev Respir Med; 2020 Jun; 14(6):547-557. PubMed ID: 32154747 [No Abstract] [Full Text] [Related]
32. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
33. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. O'Reilly R; Elphick HE Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402 [TBL] [Abstract][Full Text] [Related]
34. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Kotha K; Clancy JP Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658 [TBL] [Abstract][Full Text] [Related]
35. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
36. Targeted therapies to improve CFTR function in cystic fibrosis. Brodlie M; Haq IJ; Roberts K; Elborn JS Genome Med; 2015 Sep; 7():101. PubMed ID: 26403534 [TBL] [Abstract][Full Text] [Related]
37. [Cystic fibrosis: new treatments targeting the CFTR protein]. Fajac I; Sermet-Gaudelus I Rev Mal Respir; 2013 Apr; 30(4):255-61. PubMed ID: 23664284 [TBL] [Abstract][Full Text] [Related]
38. COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No. Thursfield RM; Shafi N; Davies JC Chest; 2022 Jan; 161(1):21-24. PubMed ID: 35000702 [No Abstract] [Full Text] [Related]
39. Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era. Wilson A; Altman K; Schindler T; Schwarzenberg SJ Clin Chest Med; 2022 Dec; 43(4):727-742. PubMed ID: 36344077 [TBL] [Abstract][Full Text] [Related]